Hypomyelination with atrophy of basal ganglia and cerebellum

Hypomyelination with atrophy of basal ganglia and cerebellum (H-ABC), also known as TUBB4A-related leukodystrophy, is an extremely rare neurological disorder characterized by deficient formation of myelin (the protective covering of nerve fibers) in the brain, combined with progressive shrinkage (atrophy) of the basal ganglia and cerebellum. It is caused by mutations in the TUBB4A gene, which encodes a tubulin protein essential for the structural framework of cells in the central nervous system. The disease primarily affects the brain and nervous system, leading to progressive neurological deterioration. Key clinical features typically emerge in infancy or early childhood and include progressive movement difficulties such as dystonia (involuntary muscle contractions), spasticity, choreoathetosis (irregular writhing movements), and ataxia (impaired coordination). Affected individuals often experience delayed motor development or regression of previously acquired motor skills. Speech and language development are frequently impaired, and cognitive decline may occur over time. Some patients develop seizures. The severity and rate of progression can vary, with some individuals presenting in infancy with severe symptoms and others having a more slowly progressive course. There is currently no cure or disease-modifying treatment for H-ABC. Management is supportive and symptomatic, focusing on physical therapy, occupational therapy, speech therapy, and medications to manage dystonia, spasticity, and seizures. Multidisciplinary care involving neurologists, rehabilitation specialists, and other healthcare providers is essential to optimize quality of life. Research into the underlying mechanisms of TUBB4A-related disorders is ongoing, but no targeted therapies are yet available.

Common questions about Hypomyelination with atrophy of basal ganglia and cerebellum